This review summarizes evidence from 2 lines of research previously thought to be unrelated: the unexpectedly positive results of TACT (Trial to Assess Chelation Therapy), and a body of epidemiological data showing that accumulation of biologically active metals, such as lead and cadmium, is an important risk factor for cardiovascular disease. Considering these 2 areas of work together may lead to the identification of new, modifiable risk factors for atherosclerotic cardiovascular disease. We examine the history of chelation up through the report of TACT. We then describe work connecting higher metal levels in the body with the future risk of cardiovascular disease. We conclude by presenting a brief overview of a newly planned National Institutes of Health trial, TACT2, in which we will attempt to replicate the findings of TACT and to establish that removal of toxic metal stores from the body is a plausible mechanistic explanation for the benefits of edetate disodium treatment. (J Am Coll Cardiol 2016;67:2411-8)
Heart, Lung, and Blood Institute for the study was that it was being conducted to prove that chelation did not work, so that the many patients who sought out this therapy every year would be armed against the unjustified assertions of those in the alternative medicine community who promoted its use. The skeptical reactions to the positive TACT results were mostly focused in 2 areas: 1) technical issues regarding blinding, high dropout rates, differential follow-up, and other trial conduct issues; and 2) the lack of a plausible mechanism by which ethylenediaminetetraacetic acid chelation could cause the observed benefit. The former issues were addressed at length in the primary TACT publication in 2013 and in its online appendix (2) . The most important issue centered on a 17% consent withdrawal rate.
Consent withdrawal, however, was more likely in the placebo patients, thus preventing attribution of more events in the placebo group than in the chelation group. This introduced a conservative bias, likely reducing the observed effect size of the active treatment. The latter criticism, lack of mechanism, reflected a prevalent confusion in medicine about the We believe that considering these 2 areas of work together may lead to the identification of a major new modifiable risk factor for atherosclerotic cardiovascular disease. We start by reviewing the history of chelation up through the report of TACT. We then describe work connecting higher metal levels in the body with the future risk of cardiovascular disease. We conclude by presenting a brief overview of a newly funded National Institutes of Health trial, TACT2, in which we will attempt to replicate the findings of TACT and establish that removal of toxic metal stores from the body is a plausible mechanistic explanation for the benefits of edetate disodium treatment. Because of the expectation that TACT would be a debunking study, it was designed as a clinical trial without a mechanistic component.
BRIEF HISTORY OF CHELATION

DESIGN AND RESULTS OF TACT
The request for applications called for testing the With regard to safety, the masked medical monitor attributed 2 deaths to study therapy: 1 was in the chelation group, and 1 in placebo.
RESULTS IN PATIENTS WITH DIABETES
A total of 633 TACT participants (37%) had diabetes, a pre-specified subgroup. Diabetes was pre-specified because it confers increased risk for cardiovascular events, and not due to any information available to 
WHAT DOES EDETATE DISODIUM CHELATE?
Although the treatment regimens tested in TACT were complex, the most reasonable presumption is that edetate disodium was the primary active thera- Compared with baseline, a single infusion increased lead excretion by 3,887%, and cadmium by 670%.
These findings raise the possibility that edetate disodium mobilizes lead and cadmium from their chronic tissue storage compartments and facilitates their excretion. In our review, we focus on cadmium and lead because those are the metals with the strongest epidemiological and experimental evidence in support of a role in cardiovascular disease development.
EVIDENCE SUPPORTING TOXIC METALS AS AN EMERGING CARDIOVASCULAR RISK FACTOR
The association of environmental pollutants, including metals, with cardiovascular disease has been reviewed elsewhere (21, 22) . In this review, we will summarize the evidence for the 2 metals that are there was a 36% increase in coronary heart disease mortality in men, but no increase was observed in women. In NHANES 1999 to 2004, however, blood and urine cadmium were associated with increased cardiovascular disease mortality, including coronary heart disease, in both men and women. In the Strong Heart Study, participants with diabetes showed stronger associations between cadmium and CVD outcomes than did those without diabetes, and the difference was statistically significant (42) .
Cadmium exposure has also been related to peripheral arterial disease. In NHANES analyses, it was proposed that cadmium could potentially mediate at least part of the effect of smoking on peripheral arterial disease (41) . A recent systematic review concluded that the evidence supports the role of cadmium as a cardiovascular disease risk factor, especially for coronary heart disease (43).
Cadmium is thought to promote atherosclerosis through oxidative mechanisms (44) . Cadmium can indirectly deplete antioxidants, such as glutathione, increasing reactive oxygen species (Central Illustration) (45) . Subclinically, cadmium has been related to early atherosclerosis, including higher carotid intima-media thickness and carotid plaque in women from Europe (44) . In experimental studies, The resultant oxidized end-products accumulate in tissues, where they promote inflammation and oxidative stress, hallmarks of atherosclerosis. These processes may provide a plausible explanation for the amplified benefit seen with edetate chelation in the diabetic subgroup of TACT (18, 52, 53) . This is a hypothesis that merits testing. A direct connection to lead and cadmium has yet to be demonstrated. placebo. TACT2 will also begin to explore the most likely mechanistic hypotheses. We have proposed blood and urine collections throughout the infusion period and will attempt to relate baseline lead and cadmium levels to risk of future events. In addition, we will perform analyses to determine whether reduction in lead and cadmium levels is causally associated with reduced cardiovascular risk. In recognition that these are hypotheses that may be disproven, a biorepository of specimens, including deoxyribonucleic acid (DNA), has also been proposed.
REPLICATION OF TACT: THE TACT2 STUDY
If fully funded, the final protocol will crystallize over the coming months. At present, TACT2 is still seeking enrollment sites.
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